Skip to main content

Featured

Wall Street Holds Steady as S&P 500 Hits Record Ahead of Christmas Break

Market Snapshot – December 24, 2025 Dow Jones Futures: Flat at 48,735 points S&P 500 Futures: Near 6,957 points, little changed after Tuesday’s record close Nasdaq 100 Futures: Slight dip of 0.1% to 25,796.5 points S&P 500 Index: Closed Tuesday at 6,909, its latest all-time high Key Drivers Robust economic growth continues to fuel investor optimism. Seasonal “Santa Claus rally” has lifted stocks for four consecutive sessions. Markets will close early today at 1 p.m. EST and remain shut tomorrow for Christmas Day. Traders remain cautious about inflation and potential Federal Reserve rate cuts in 2026. Quick Take Wall Street enters the holiday season on a high note, with the S&P 500 near the 7,000 mark and futures showing little movement. The shortened trading session means liquidity will be thin, amplifying small moves. Still, the overall tone remains upbeat, with investors betting that the year-end rally will carry into the final days of 2025.

article

New Cystic Fibrosis Drug Offers Hope, but Comes with a High Price

A new drug for cystic fibrosis, Trikafta, is providing significant hope for patients suffering from the genetic disorder. Trikafta has been shown to reduce hospital visits and improve overall lung function, offering patients a better quality of life. For those living with cystic fibrosis, which affects the respiratory and digestive systems, this advancement is nothing short of a breakthrough.

However, the cost of Trikafta is a major concern. Priced at around $300,000 per year, the drug is prohibitively expensive for many patients and their families. While some health programs and insurance plans may cover the cost, access to this life-changing medication remains a challenge.

As the debate over drug pricing and healthcare accessibility continues, the medical community and patient advocacy groups are calling for measures to ensure that Trikafta is available to all who need it, regardless of their financial situation.


Comments